fda bpc-157 category 2 bulk drug substance compounding list An advisory committee voted Thursday to remove restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8-6 votes (with The Food and Drug Administration's
The Food and Drug Administration's committee on compounded drugs broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make. Follow the link FDA Peptide Reclassification 2026: What Researchers Want FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for FDA considers adding a dozen peptides to its bulk drug compounding list RAPS
Pay in 4 interest-free payments of $6.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13

